PMID- 28986743
OWN - NLM
STAT- MEDLINE
DCOM- 20181025
LR  - 20200806
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 167
IP  - 2
DP  - 2018 Jan
TI  - Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and 
      predictive impact.
PG  - 547-554
LID - 10.1007/s10549-017-4520-1 [doi]
AB  - PURPOSE: HER2 copy number by fluorescence in situ hybridization (FISH) is 
      typically reported relative to the centromere enumeration probe 17 (CEP17). 
      HER2/CEP17 ratio could be impacted by alterations in the number of chromosome 17 
      copies. Monosomy of chromosome 17 (m17) is found in ~ 1900 cases of early-stage 
      HER2-positive breast cancer annually in the United States; however, the efficacy 
      of HER2-directed trastuzumab therapy in these patients is not well characterized. 
      Here, we retrospectively identified HER2-amplified, stage I-III breast cancers 
      with m17 and characterized the impact of trastuzumab treatment. METHODS: From 
      January 1, 2000 to June 1, 2011, we identified 99 women with HER2-amplified m17 
      breast cancers, as defined by a CEP17 signal of < 1.5 per nucleus and a 
      HER2/CEP17 ratio of >/= 2.0. RESULTS: Most HER2-amplified m17 patients were treated 
      with trastuzumab plus chemotherapy (51%, n = 50), whereas 31% (n = 31) received 
      chemotherapy alone and 18% (n = 18) received no chemotherapy. The 4-year overall 
      survival (OS) was superior with trastuzumab compared to chemotherapy alone or no 
      chemotherapy (100 vs. 93 vs. 81%, respectively; p = 0.005). OS was not influenced 
      by estrogen/progesterone-receptor (ER/PR) status, tumor stage, or degree of FISH 
      positivity. A proportion of patients who would be considered HER2-negative by 
      standard immunohistochemistry staging criteria (0-1+) were HER2 amplified by 
      FISH. CONCLUSIONS: In the largest series reported to date, patients with 
      HER2-amplified m17 cancers treated with trastuzumab have outcomes comparable to 
      patients from the large phase III adjuvant trastuzumab trials who were 
      HER2-positive, supporting the critical role of HER2-directed therapy in this 
      patient population.
FAU - Page, David B
AU  - Page DB
AD  - Providence Cancer Center, Earle A. Chiles Research Institute, 4805 NE Glisan St., 
      Suite 6N40, Portland, OR, 97213, USA. David.Page2@providence.org.
FAU - Wen, Hannah
AU  - Wen H
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - Brogi, Edi
AU  - Brogi E
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - Dure, Dana
AU  - Dure D
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - Ross, Dara
AU  - Ross D
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - Spinelli, Kateri J
AU  - Spinelli KJ
AD  - Providence Cancer Center, Earle A. Chiles Research Institute, 4805 NE Glisan St., 
      Suite 6N40, Portland, OR, 97213, USA.
FAU - Patil, Sujata
AU  - Patil S
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - Norton, Larry
AU  - Norton L
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - Hudis, Clifford
AU  - Hudis C
AD  - Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, 
      USA.
FAU - McArthur, Heather L
AU  - McArthur HL
AD  - Cedars-Sinai Medical Center, 8700 Beverly Blvd, AC 1042B, Los Angeles, CA, 90048, 
      USA. heather.mcarthur@cshs.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30CA008748/Cancer Center Support National Institutes of Health/National Cancer 
      Institute/International
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171006
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*drug therapy/genetics/pathology/therapy
MH  - Chromosomes, Human, Pair 17/genetics
MH  - Female
MH  - Gene Amplification/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Monosomy/genetics
MH  - *Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Trastuzumab/*therapeutic use
PMC - PMC7405897
MID - NIHMS1611329
OTO - NOTNLM
OT  - Aneusomy 17
OT  - CEP17
OT  - Chromosome 17
OT  - FISH
OT  - HER2
OT  - HER2-amplified
OT  - Monosomy 17
OT  - Polysomy 17
OT  - Trastuzumab
COIS- Conflict of Interest: The authors declare that they have no conflict of interest.
EDAT- 2017/10/08 06:00
MHDA- 2018/10/26 06:00
PMCR- 2020/08/05
CRDT- 2017/10/08 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2017/09/21 00:00 [accepted]
PHST- 2017/10/08 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2017/10/08 06:00 [entrez]
PHST- 2020/08/05 00:00 [pmc-release]
AID - 10.1007/s10549-017-4520-1 [pii]
AID - 10.1007/s10549-017-4520-1 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2018 Jan;167(2):547-554. doi: 10.1007/s10549-017-4520-1. 
      Epub 2017 Oct 6.